A Dose-Escalation Study in Participants With Recurrent Malignant Glioma

NCT01682187 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioma

Interventions

DRUG: LY2157299
DRUG: Lomustine

Sponsor

Eli Lilly and Company